新光药业(300519) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥86,767,854.59, representing a 3.12% increase year-over-year[3] - The net profit attributable to shareholders for Q3 2021 was ¥30,962,272.01, reflecting a 6.02% increase compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,125,035.63, up 8.41% year-over-year[3] - Total operating revenue for Q3 2021 reached ¥246,270,270.66, an increase of 15.87% compared to ¥212,577,989.27 in the same period last year[21] - Net profit for Q3 2021 was ¥87,978,147.82, representing a growth of 16.67% from ¥75,224,412.94 in Q3 2020[22] - Basic and diluted earnings per share for Q3 2021 were both ¥0.55, compared to ¥0.47 in the same quarter last year, indicating a 17.02% increase[22] - The total comprehensive income for Q3 2021 was ¥88,044,443.46, compared to ¥75,090,392.75 in Q3 2020, representing an increase of 17.19%[22] Assets and Liabilities - The total assets at the end of Q3 2021 were ¥888,296,595.54, showing a slight decrease of 0.28% from the end of the previous year[4] - Total liabilities as of the end of Q3 2021 were ¥68,989,437.88, an increase from ¥63,842,966.27 at the end of the previous year, marking an increase of 16.83%[21] - Total equity attributable to shareholders of the parent company was ¥819,307,157.66, slightly down from ¥826,942,714.20, a decrease of 0.79%[21] - The company's cash and cash equivalents decreased to CNY 555,128,438.39 from CNY 591,847,788.22, reflecting a decline of approximately 6%[18] - The company's inventory decreased to CNY 36,312,888.47 from CNY 42,922,294.17, representing a reduction of about 15%[19] - The company's accounts receivable increased to CNY 22,139,611.68 from CNY 19,034,823.44, indicating an increase of approximately 11%[19] Cash Flow - The cash flow from operating activities for the year-to-date was ¥99,980,133.44, an increase of 33.84% compared to the same period last year[3] - Operating cash flow net amount increased to ¥99,980,133.44 from ¥74,699,705.67, representing a growth of approximately 33.5%[24] - Cash inflow from operating activities totaled ¥238,797,032.24, up from ¥201,742,859.41, indicating an increase of about 18.4%[24] - Cash outflow from operating activities rose to ¥138,816,898.80 compared to ¥127,043,153.74, reflecting an increase of approximately 9.0%[24] - The net increase in cash and cash equivalents was -¥36,719,349.83, contrasting with an increase of ¥122,355,222.92 in the previous period[25] Investments and Expenses - The company reported a significant increase of 41.18% in trading financial assets, totaling ¥120,000,000.00 due to the purchase of bank wealth management products[8] - The company experienced a 67.99% increase in prepayments, amounting to ¥3,480,105.40, primarily due to increased advertising expenses[8] - The company’s financial expenses decreased by 30.65% to -¥6,318,145.56, mainly due to reduced bank deposit interest[9] - The net cash flow from investing activities was -¥40,699,483.27, a decrease of 134.01% year-over-year, attributed to increased purchases of wealth management products[9] - Cash outflow from investment activities increased to ¥272,775,103.72 from ¥117,042,416.40, marking a rise of about 133.3%[25] - The company paid ¥96,000,000.00 in dividends, an increase from ¥72,000,000.00, representing a growth of 33.3%[25] Research and Development - Research and development expenses for Q3 2021 were ¥9,450,187.40, compared to ¥8,492,306.92 in Q3 2020, reflecting a year-over-year increase of 11.29%[22] Other Information - The company reported a significant loss of inventory due to flooding, affecting products such as Huangqi Shengmai Liquid and Western Ginseng Liquid[16] - The company has initiated the establishment of a special account for raised funds related to the "Modern Chinese Medicine R&D Center Construction Project" with a transfer of CNY 32,864,800 from other projects[16] - The company did not undergo an audit for the third quarter report[26]